Follow-Up of SARS-CoV-2 Antibody Levels in Belgian Nursing Home Residents and Staff Two, Four and Six Months after Primary Course BNT162b2 Vaccination.
Meyers, Eline; De Rop, Liselore; Engels, Fienet al.
COVID-19 vaccination; SARS-CoV-2 antibodies; nursing home residents; nursing home staff; Immunology; Pharmacology; Drug Discovery; Infectious Diseases; Pharmacology (medical)
Abstract :
[en] When COVID-19 vaccines were implemented, nursing home residents (NHRs) and staff (NHS) in Belgium were prioritized for vaccination. To characterize the vaccine response over time in this population and to identify poorly responding groups, we assessed antibody concentrations two (T1), four (T2) and six months (T3) after primary course BNT162b2 vaccination in six groups of infection-naive/infection-primed NHRs/NHS, with/without comorbidity (NHRs only). Participant groups (N = 125 per group) were defined within a national serosurveillance study in nursing homes, based on questionnaire data. Dried blood spots were analyzed using ELISA for the quantification of SARS-CoV-2 S1RBD IgG antibodies. Among all groups, antibody concentrations significantly decreased between T1 and T2/T3, all with a ≥70% decrease at T3, except for infection-primed staff (-32%). Antibody concentrations among infection-naive NHRs were 11.96 times lower than those among infection-primed NHR, while the latter were comparable (x1.05) to infection-primed NHS. The largest proportion [13% (95% CI: 11-24%)] of vaccine non-responders was observed in the group of infection-naive NHRs with comorbidities. A longer interval between infection and vaccination (≥3 months) elicited higher antibody responses. Our data retrospectively show the necessity of timely COVID-19 booster vaccination. Infection-naive NHRs require special attention regarding immune monitoring in future epidemics or pandemics.
Disciplines :
Immunology & infectious disease
Author, co-author :
Meyers, Eline ; Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
De Rop, Liselore ; EPI-Centre, Department of Public Health and Primary Care, KU Leuven, 3000 Leuven, Belgium
Engels, Fien; Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Gioveni, Claudia; Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Coen, Anja; Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
De Burghgraeve, Tine; EPI-Centre, Department of Public Health and Primary Care, KU Leuven, 3000 Leuven, Belgium
Van Ngoc, Pauline ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
De Clercq, Nele; Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Buret, Laetitia ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Coenen, Samuel ; Department of Family Medicine & Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, 2000 Antwerp, Belgium
Deschepper, Ellen; Biostatistics Unit, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Padalko, Elizaveta; Laboratory of Medical Microbiology, Ghent University Hospital, 9000 Ghent, Belgium
Callens, Steven ; Department of Internal Medicine & Infectious Diseases, Ghent University Hospital, 9000 Ghent, Belgium
Duysburgh, Els; Department of Epidemiology and Public Health, Sciensano, 1000 Brussels, Belgium
De Sutter, An; Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Scholtes, Béatrice ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Verbakel, Jan Y ; EPI-Centre, Department of Public Health and Primary Care, KU Leuven, 3000 Leuven, Belgium
Heytens, Stefan ; Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Cools, Piet ; Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Follow-Up of SARS-CoV-2 Antibody Levels in Belgian Nursing Home Residents and Staff Two, Four and Six Months after Primary Course BNT162b2 Vaccination.
Sciensano UZ Gent - Ghent University Hospital FWO - Research Foundation Flanders
Funding text :
This study was funded by Sciensano (SC_045), Ghent University Hospital COVID-19 foundation (KW/2011/CIZ/005/001) and the Research Foundation Flanders (1SDN2524N).
Catteau L. Haarhuis F. Dequeker S. Vandael E. Stouten V. Litzroth A. Wyndham Thomas C. Surveillance de la Vaccination COVID-19 Dans les Maisons de Repos et Maisons de Repos et de Soins Belges Sciensano Bruxelles, Belgique 2021
Polack F.P. Thomas S.J. Kitchin N. Absalon J. Gurtman A. Lockhart S. Perez J.L. Pérez Marc G. Moreira E.D. Zerbini C. et al. Safety and Efficacy of the BNT162b2 mRNsA COVID-19 Vaccine N. Engl. J. Med. 2020 383 2603 2615 10.1056/NEJMoa2034577
Walsh E.E. Frenck R.W. Jr. Falsey A.R. Kitchin N. Absalon J. Gurtman A. Lockhart S. Neuzil K. Mulligan M.J. Bailey R. et al. Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates N. Engl. J. Med. 2020 383 2439 2450 10.1056/NEJMoa2027906
High K.P. Fulop T. Pawelec G. Castle S. Loeb M. Immunosenescence and Vaccination in Nursing Home Residents Clin. Infect. Dis. 2009 48 443 448 10.1086/596475
Thomas S.J. Moreira E.D. Kitchin N. Absalon J. Gurtman A. Lockhart S. Perez J.L. Pérez Marc G. Polack F.P. Zerbini C. et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months N. Engl. J. Med. 2021 385 1761 1773 10.1056/NEJMoa2110345
Nanduri S. Pilishvili T. Derado G. Soe M.M. Dollard P. Wu H. Li Q. Bagchi S. Dubendris H. Link-Gelles R. et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variants—National Healthcare Safety Network, March 1–August 1, 2021 MMWR Morb. Mortal. Wkly. Rep. 2021 70 1163 1166
European Centre for Disease Prevention and Control Overview of the Implementation of COVID-19 Vaccination Strategies and Deployment Plans in the EU/EEA ECDC Stockholm, Sweden 2022
Meyers E. De Rop L. Deschepper E. Duysburgh E. De Burghgraeve T. Van Ngoc P. Digregorio M. Delogne S. Coen A. De Clercq N. et al. Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign Eur. J. Gen. Pract. 2022 29 2149732 10.1080/13814788.2022.2149732
Meyers E. Coen A. De Sutter A. Padalko E. Callens S. Vandekerckhove L. Witkowski W. Heytens S. Cools P. Diagnostic performance of the SARS-CoV-2 S1RBD IgG ELISA (ImmunoDiagnostics) for the quantitative detection of SARS-CoV-2 antibodies on dried blood spots J. Clin. Virol. 2022 155 105270 10.1016/j.jcv.2022.105270
Meyers E. Heytens S. Formukong A. Vercruysse H. Sutter A.D. Geens T. Hofkens K. Janssens H. Nys E. Padalko E. et al. Comparison of Dried Blood Spots and Venous Blood for the Detection of SARS-CoV-2 Antibodies in a Population of Nursing Home Residents Microbiol. Spectr. 2021 9 e0017821 10.1128/Spectrum.00178-21
ImmunoDiagnostics SARS-CoV-2 S1RBD IgG ELISA Kit (Cat No. 41A235): Instruction Manual 2021 Available online: https://352e17ab-a8e4-46c2-80bb-92cf412fb1dd.filesusr.com/ugd/0fbcf2_d3b49a04680e49579196c889886f61bf.pdf (accessed on 6 August 2024)
Anichini G. Terrosi C. Gandolfo C. Gori Savellini G. Fabrizi S. Miceli G.B. Cusi M.G. SARS-CoV-2 Antibody Response in Persons with Past Natural Infection N. Engl. J. Med. 2021 385 90 92 10.1056/NEJMc2103825
Meyers E. Deschepper E. Duysburgh E. De Rop L. De Burghgraeve T. Van Ngoc P. Digregorio M. Delogne S. Coen A. De Clercq N. et al. Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective Cohort Study Viruses 2022 14 2361 10.3390/v14112361
Pannus P. Neven K.Y. De Craeye S. Heyndrickx L. Vande Kerckhove S. Georges D. Michiels J. Francotte A. Van Den Bulcke M. Zrein M. et al. Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2–Naive Residents of Nursing Homes Clin. Infect. Dis. 2021 75 e695 e704 10.1093/cid/ciab998
Gallichotte E.N. Nehring M. Stromberg S. Young M.C. Snell A. Daniels J. Pabilonia K.L. VandeWoude S. Ehrhart N. Ebel G.D. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff mSphere 2022 7 e0016922 10.1128/msphere.00169-22
Canaday D.H. Carias L. Oyebanji O.A. Keresztesy D. Wilk D. Payne M. Aung H. St. Denis K. Lam E.C. Rowley C.F. et al. Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home Residents Clin. Infect. Dis. 2021 73 2112 2115 10.1093/cid/ciab447
Witkowski W. Gerlo S. De Smet E. Wejda M. Acar D. Callens S. Heytens S. Padalko E. Vercruysse H. Cools P. et al. Humoral and Cellular Responses to COVID-19 Vaccination Indicate the Need for Post-Vaccination Testing in Frail Population Vaccines 2022 10 260 10.3390/vaccines10020260
Goldblatt D. Alter G. Crotty S. Plotkin S.A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease Immunol. Rev. 2022 310 6 26 10.1111/imr.13091
Regev-Yochay G. Lustig Y. Joseph G. Gilboa M. Barda N. Gens I. Indenbaum V. Halpern O. Katz-Likvornik S. Levin T. et al. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): A prospective cohort study Lancet Microbe 2023 4 e309 e318 10.1016/S2666-5247(23)00012-5
Earle K.A. Ambrosino D.M. Fiore-Gartland A. Goldblatt D. Gilbert P.B. Siber G.R. Dull P. Plotkin S.A. Evidence for antibody as a protective correlate for COVID-19 vaccines Vaccine 2021 39 4423 4428 10.1016/j.vaccine.2021.05.063
Goldblatt D. Fiore-Gartland A. Johnson M. Hunt A. Bengt C. Zavadska D. Snipe H.D. Brown J.S. Workman L. Zar H.J. et al. Towards a population-based threshold of protection for COVID-19 vaccines Vaccine 2022 40 306 315 10.1016/j.vaccine.2021.12.006
Khoury D.S. Cromer D. Reynaldi A. Schlub T.E. Wheatley A.K. Juno J.A. Subbarao K. Kent S.J. Triccas J.A. Davenport M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Nat. Med. 2021 27 1205 1211 10.1038/s41591-021-01377-8
Bálint G. Vörös-Horváth B. Széchenyi A. Omicron: Increased transmissibility and decreased pathogenicity Signal Transduct. Target. Ther. 2022 7 151 10.1038/s41392-022-01009-8
Chong Y. Goto T. Tani N. Yonekawa A. Ikematsu H. Shimono N. Tanaka Y. Akashi K. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents Influenza Other Respir. Viruses 2022 16 1066 1071 10.1111/irv.13030
Canaday D.H. Oyebanji O.A. White E. Keresztesy D. Payne M. Wilk D. Carias L. Aung H. St Denis K. Sheehan M.L. et al. Significantly elevated antibody levels and neutralization titers in nursing home residents after SARS-CoV-2 BNT162b2 mRNA booster vaccination medRxiv 2021 10.1101/2021.12.07.21267179
Sun Z. Wu T. Xie H. Li Y. Zhang J. Su X. Qi H. The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines Vaccines 2022 10 1103 10.3390/vaccines10071103
Kemlin D. Gemander N. Depickère S. Olislagers V. Georges D. Waegemans A. Pannus P. Lemy A. Goossens M.E. Desombere I. et al. Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients Am. J. Transplant. 2023 23 649 658 10.1016/j.ajt.2023.02.015
Kent S.J. Khoury D.S. Reynaldi A. Juno J.A. Wheatley A.K. Stadler E. John Wherry E. Triccas J. Sasson S.C. Cromer D. et al. Disentangling the relative importance of T cell responses in COVID-19: Leading actors or supporting cast? Nat. Rev. Immunol. 2022 22 387 397 10.1038/s41577-022-00716-1
Wherry E.J. Barouch D.H. T cell immunity to COVID-19 vaccines Science 2022 377 821 822 10.1126/science.add2897
Hermens J.M. Kesmir C. Role of T cells in severe COVID-19 disease, protection, and long term immunity Immunogenetics 2023 75 295 307 10.1007/s00251-023-01294-9
Sciensano Belgium COVID-19 Epidemiological Situation Available online: https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/cUWaB (accessed on 1 September 2023)
Stellini R. Gianello R. Meloni A. Croce E. Materzanini P. Gomarasca W. Prior SARS-CoV-2 infection increases reactogenicity after SARS-Cov-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection Infection 2022 50 791 793 10.1007/s15010-021-01729-z
Tuaillon E. Pisoni A. Veyrenche N. Rafasse S. Niel C. Gros N. Muriaux D. Picot M.-C. Aouinti S. Van de Perre P. et al. Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents Sci. Rep. 2022 12 13749 10.1038/s41598-022-18041-x
Parry H. Bruton R. Stephens C. Bentley C. Brown K. Amirthalingam G. Hallis B. Otter A. Zuo J. Moss P. Extended interval BNT162b2 vaccination enhances peak antibody generation Npj Vaccines 2022 7 14 10.1038/s41541-022-00432-w
Payne R.P. Longet S. Austin J.A. Skelly D.T. Dejnirattisai W. Adele S. Meardon N. Faustini S. Al-Taei S. Moore S.C. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine Cell 2021 184 5699 5714.e11 10.1016/j.cell.2021.10.011 34735795
Soegiarto G. Wulandari L. Purnomosari D. Dhia Fahmita K. Ikhwan Gautama H. Tri Hadmoko S. Edwin Prasetyo M. Aulia Mahdi B. Arafah N. Prasetyaningtyas D. et al. Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2 Vaccine 2022 40 4046 4056 10.1016/j.vaccine.2022.05.059 35660034
Watanabe M. Balena A. Tuccinardi D. Tozzi R. Risi R. Masi D. Caputi A. Rossetti R. Spoltore M.E. Filippi V. et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine Diabetes/Metab. Res. Rev. 2022 38 e3465 10.1002/dmrr.3465
Yelin I. Katz R. Herzel E. Berman-Zilberstein T. Ben-Tov A. Kuint J. Gazit S. Patalon T. Chodick G. Kishony R. Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities medRxiv 2021 10.1101/2021.03.16.21253686
Guzik T.J. Hoch N.E. Brown K.A. McCann L.A. Rahman A. Dikalov S. Goronzy J. Weyand C. Harrison D.G. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction J. Exp. Med. 2007 204 2449 2460 10.1084/jem.20070657
Wen Y. Crowley S.D. Renal effects of cytokines in hypertension Curr. Opin. Nephrol. Hypertens. 2018 27 70 76 10.1097/MNH.0000000000000385 29140820
Xia S. Zhang X. Zheng S. Khanabdali R. Kalionis B. Wu J. Wan W. Tai X. An Update on Inflamm-Aging: Mechanisms, Prevention, and Treatment J. Immunol. Res. 2016 2016 8426874 10.1155/2016/8426874
Tizazu A.M. Mengist H.M. Demeke G. Aging, inflammaging and immunosenescence as risk factors of severe COVID-19 Immun. Ageing 2022 19 53 10.1186/s12979-022-00309-5
Teissier T. Boulanger E. Cox L.S. Interconnections between Inflammageing and Immunosenescence during Ageing Cells 2022 11 359 10.3390/cells11030359
Bryniarski P. Nazimek K. Marcinkiewicz J. Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Int. J. Mol. Sci. 2022 23 1772 10.3390/ijms23031772
Felkle D. Jarczyński M. Kaleta K. Zięba K. Nazimek K. The immunomodulatory effects of antihypertensive therapy: A review Biomed. Pharmacother. 2022 153 113287 10.1016/j.biopha.2022.113287 35728352
Naruse H. Ito H. Izawa H. Sarai M. Ishii J. Sakaguchi E. Murakami R. Ando T. Fujigaki H. Saito K. Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease J. Clin. Med. 2021 10 5498 10.3390/jcm10235498 34884205
Li C. Bi H. Fu Z. Li A. Wan N. Hu J. Yang F. Zhou T.-C. Liang Y. Su W. et al. Retrospective study of the immunogenicity and safety of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions Commun. Med. 2022 2 151 10.1038/s43856-022-00216-2 36434092
Amraotkar A.R. Bushau-Sprinkle A.M. Keith R.J. Hamorsky K.T. Palmer K.E. Gao H. Rai S.N. Bhatnagar A. Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 Vaccination Vaccines 2022 10 1363 10.3390/vaccines10081363
Harboe Z.B. Hamm S.R. Pérez-Alós L. Sivapalan P. Priemé H. Wilcke T. Kjeldgaard P. Shaker S. Svorre Jordan A. Møller D.L. et al. Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases BMJ Open Respir. Res. 2022 9 e001268 10.1136/bmjresp-2022-001268
